We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

26 hedge funds and large institutions have $16M invested in Avalo Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

37% more funds holding

Funds holding: 19 → 26 (+7)

0.04% more ownership

Funds ownership: 0.25% → 0.29% (+0.04%)

43% less capital invested

Capital invested by funds: $28M → $16M (-$12M)

Holders
26
Holders Change
+7
Holders Change %
+36.84%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$3.28M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.97M
3
GPP
Great Point Partners
Connecticut
+$1.56M
4
AC
Armistice Capital
New York
+$1.48M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.31M

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$95K
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$79K
3
UBS Group
UBS Group
Switzerland
-$12.6K
4
MAM
Meeder Asset Management
Ohio
-$4.73K
5
Goldman Sachs
Goldman Sachs
New York
-$3.15K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$7.73M +$1.48M +1,877 +11%
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$1.93M +$1.97M +2,500 +120%
VA
3
VR Adviser
New York
$1.75M +$3.28M +4,167 New
NCM
4
Nantahala Capital Management
Connecticut
$1.42M +$880K +1,117 +50%
GPP
5
Great Point Partners
Connecticut
$831K +$1.56M +1,978 New
Alyeska Investment Group
6
Alyeska Investment Group
Illinois
$700K +$1.31M +1,667 New
B
7
Braidwell
Connecticut
$433K +$811K +1,030 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$389K – – –
BlackRock
9
BlackRock
New York
$180K – – –
MS
10
Maven Securities
Jersey
$163K +$305K +387 New
Millennium Management
11
Millennium Management
New York
$109K +$63K +80 +44%
MIM
12
Monashee Investment Management
Massachusetts
$105K +$197K +250 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$89.8K – – –
Goldman Sachs
14
Goldman Sachs
New York
$56.5K -$3.15K -4 -3%
State Street
15
State Street
Massachusetts
$44.9K – – –
Morgan Stanley
16
Morgan Stanley
New York
$21.6K -$788 -1 -2%
Northern Trust
17
Northern Trust
Illinois
$19K – – –
Bank of America
18
Bank of America
North Carolina
$7.54K +$14.2K +18 New
UBS Group
19
UBS Group
Switzerland
$4.11K -$12.6K -16 -62%
TRCT
20
Tower Research Capital (TRC)
New York
$4K +$7.88K +10 New
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$2K +$2.36K +3 +150%
Osaic Holdings
22
Osaic Holdings
Arizona
$584 +$788 +1 New
FHA
23
First Horizon Advisors
Tennessee
$483 +$788 +1 New
TWA
24
TCI Wealth Advisors
Arizona
$440 – – –
Group One Trading
25
Group One Trading
Illinois
$305 – – –
1
2

AVTX Hedge Fund Activity: Q1 2023 in Review

26 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q1 2023, worth a combined $16M — down 43% from $28M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new AVTX positions and 3 closed out — a net gain of 7 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $3.28M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $95K sold.

  • 26 institutional investors held Avalo Therapeutics (AVTX) as of Q1 2023, up from 19 in Q4 2022.
  • Funds reported $16M of Avalo Therapeutics stock for Q1 2023, down 43% quarter-over-quarter.
  • 10 funds opened new Avalo Therapeutics positions in Q1 2023 and 3 closed out, a net change of +7 holders.
  • The largest Avalo Therapeutics buyer in Q1 2023 was VR Adviser, an estimated $3.28M added.
  • The largest Avalo Therapeutics seller in Q1 2023 was Susquehanna International Group, an estimated $95K sold.

Based on aggregated 13F filings for Q1 2023.